Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan:7:63-71.
doi: 10.1200/GO.20.00473.

Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus

Alexander I Rolevich  1 , Denis M Borodin  1 , Anton N Rabcheuski  1 , Tatsiana A Ivanitskaya  2 , Sviataslau A Semenov  1 , Liudmila V Artsiushkevich  3 , Alena V Sukalinskaya  2 , Edvard A Zhavrid  2 , Sergei A Krasny  1 , Natalia E Konoplya  3 , Sergey L Polyakov  1
Affiliations

Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus

Alexander I Rolevich et al. JCO Glob Oncol. 2021 Jan.

Abstract

Purpose: Since the development of the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification in a 1997 study, high-income countries have reported a significant increase in survival for poor prognosis patients. There are scant data on IGCCCG risk-stratified survival from low- and middle-income countries. We assessed the progression-free survival (PFS) and overall survival (OS) rates in a contemporary cohort of Belarusian patients with advanced germ cell cancer (GCC) stratified by the IGCCCG prognostic classification and analyzed prognostic factors for survival.

Materials and methods: The consecutive cohort of patients with clinical stage IIb-III testicular GCC or extragonadal germ cell tumors who received treatment or consultation in our two centers between 2010 and 2015 was included. All patients underwent primary chemotherapy. The patients were divided into seminoma and nonseminomatous germ cell carcinoma (NSGCC) subgroups. The Kaplan-Meier method was used to estimate 5-year PFS and OS.

Results: This study included 111 patients with a median age of 32 years, 95% of whom were diagnosed with testicular cancer. Seminoma and NSGCC were identified in 32 (29%) and 79 (71%) patients, respectively. The median follow-up was 6.1 years. The 5-year PFS and OS rates for the entire cohort were 70% and 77%, respectively. In patients with good prognosis seminoma and good, intermediate, and poor prognosis NSGCC, the estimated PFS rates were 76%, 88%, 74%, and 39% and those for OS were 83%, 97%, 83%, and 38%, respectively.

Conclusion: In our cohort of Belarusian patients with advanced germ cell tumors, we failed to demonstrate an improvement in PFS and OS compared with the 1997 IGCCCG study. Moreover, survival in poor prognosis group is inferior to that in IGCCCG and all contemporary series from high-income countries.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Alexander I. Rolevich

Honoraria: Sanofi/Aventis, Astellas Pharma, Roche

Sergey L. Polyakov

Honoraria: Astellas, Roche, Ferring

Research Funding: Bayer

No other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
Progression-free survival of patients according to the International Germ Cell Consensus Classification and pathology.
FIG 2
FIG 2
Overall survival of patients according to the International Germ Cell Consensus Classification and pathology.
See this image and copyright information in PMC

References

    1. Ferlay J, Ervik M, Lam F, et al. : Cancer Today. Lyon, France, Global Cancer Observatory, International Agency for Research on Cancer, 2018
    1. Hanna NH, Einhorn LH: Testicular cancer: Discoveries and updates. N Engl J Med 371:2005-2016, 2014 - PubMed
    1. Rolevich A, Yaumenenka A, Borodin D, et al. : Trends in incidence, mortality and survival of testicular cancer patients in Belarus. Cent Eur J Urol 72:357-368, 2019 - PMC - PubMed
    1. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997 - PubMed
    1. De Angelis R, Gatta G, Mallone S, et al. : Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5—A population-based study. Lancet Oncol 15:23-34, 2014 - PubMed